CD22 Assay Portfolio Service
Introduction What We Can Offer Workflow Why Creative Biolabs Customer Reviews FAQs Related Services Contact Us
Creative Biolabs provides the comprehensive data needed to characterize these critical properties, supporting the development of safe and effective new treatments. Our service is meticulously designed to provide you with a clear, data-driven path for developing anti-CD22 therapeutics. Creative Biolabs delivers precise characterization of your antibody or immunotoxin candidates, focusing on the key functional properties that dictate in vivo efficacy.
CD22 as a Target for Immunotherapy
CD22, a member of the Siglec family of inhibitory receptors, is a well-established and highly promising target for B-cell malignancy therapies due to its restricted expression on B-cells and its role in modulating BCR signaling. The success of CD22-targeting therapeutics, such as ADCs and immunotoxins, relies on a deep understanding of their binding and functional impact.
Discover how we can help - Request a consultation.
Fig.1 CD22 dependent regulation of the B-cell receptor (BCR) signal.1
What We Can Offer
Binding and Adhesion Assays
We provide a detailed analysis of your therapist's interaction with the CD22 protein. Our services include in vitro B-cell Siglec-engaging tolerance-inducing antigenic liposomes (STALs) assays, cell adhesion assays, and CD22-Fc binding assays to measure and quantify both specific binding and functional adhesion properties.
Functional Signaling and Cytotoxicity Assays
To evaluate the biological impact of your candidates, we offer a suite of functional assays. These include Ca2+ influx assays to measure downstream signaling, as well as cell proliferation and cytotoxicity assays to determine the dose-dependent effects of your therapeutic on target cells.
Protein and Cytokine Analysis
We can precisely quantify the expression and impact of your therapy using a variety of analytical tools. Our capabilities include Western blotting, flow cytometry, immunohistochemistry, and ELISA to analyze cytokine release and protein expression levels.
Workflow of CD22 Assay Portfolio Service
Highlights
Unrivaled Expertise & Strategic Insights
We provide expert analysis and interpretation, helping you understand the "why" behind the data and offering strategic guidance to navigate the challenges of B-cell malignancy research.
State-of-the-Art Technology
We utilize advanced, high-throughput screening platforms for superior data quality, sensitivity, and speed. Our optimized assays ensure reproducible and robust results, empowering you to make confident decisions and accelerate your project timeline.
A Customized, Partner-Centric Approach
Our workflow is tailored to your specific goals and therapeutic candidates. We work closely with you from initial consultation to final delivery, ensuring our service perfectly aligns with your research needs.
Actionable Data for Confident Decisions
We focus on key functional challenges like kinetics and immunogenicity, providing you with a clear, data-driven foundation for confident decision-making in your preclinical pipeline.
Discover how a partnership with us can streamline your research - Get a quote today.
Customer Reviews
-
Precision in ADC Selection
Using Creative Biolabs' service in our research has significantly improved our ability to select high-affinity antibody-drug conjugates. The detailed kinetic data were essential. - J***s E.
-
Accelerated Candidate Screening
The assays provided by Creative Biolabs facilitated the rapid identification of a therapeutic candidate with optimal endocytosis properties for our immunotoxin program. - M***a R.
FAQs
What types of therapeutic candidates can you test?
Our portfolio is designed to be highly versatile. We can analyze a wide range of therapeutic candidates, including monoclonal antibodies, ADCs, bispecific antibodies, and recombinant immunotoxins. We encourage you to reach out to our team to discuss your specific candidate.
How do your assays compare to standard in-house methods?
Our assays utilize state-of-the-art technology and have been meticulously optimized by our expert scientists, ensuring superior reproducibility, sensitivity, and speed compared to many standard in-house methods. This saves you time and resources while providing high-quality, actionable data.
Can your assays handle a large number of candidates?
Absolutely. Our high-throughput screening platform is designed to efficiently test large libraries of candidates, allowing you to rapidly identify the most promising lead compounds and accelerate your development timeline.
Related Services
Antibody-Drug Conjugate (ADC) Technology
Our comprehensive ADC platform offers end-to-end support for developing these highly potent therapeutics. This includes expert assistance with antibody selection, optimized linker design, and payload conjugation.
Learn More →
Cell Line Development
To further support your functional and cellular assays, we generate cell lines that stably express your target of interest, such as CD22, providing a robust and consistent tool for your drug screening and validation studies.
Learn More →
How to Contact Us
Our CD22 assay portfolio service helps you streamline preclinical research and confidently advance your lead candidates through advanced analytics, high-throughput screening, and functional signaling assays. We provide the robust, reproducible data you need to make informed decisions and accelerate your project to the next stage. Our team of experts is eager to discuss your project needs and design a customized solution-Contact us now!
Reference
-
Meyer, Sarah J., et al. "B cell siglecs–news on signaling and its interplay with ligand binding." Frontiers in immunology 9 (2018): 2820. Distributed under an Open Access license CC BY 4.0, without modification. DOI: https://doi.org/10.3389/fimmu.2018.02820
For Research Use Only | Not For Clinical Use
